Compare DAKT & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | EVMN |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 869.1M |
| IPO Year | 1996 | N/A |
| Metric | DAKT | EVMN |
|---|---|---|
| Price | $20.09 | $15.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $43.88 |
| AVG Volume (30 Days) | 477.1K | ★ 547.8K |
| Earning Date | 03-04-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 538.10 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | N/A |
| P/E Ratio | $21.23 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $14.87 | $13.89 |
| 52 Week High | $28.27 | $33.20 |
| Indicator | DAKT | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 32.04 |
| Support Level | $19.08 | N/A |
| Resistance Level | $20.55 | $20.37 |
| Average True Range (ATR) | 1.07 | 1.72 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 41.18 | 0.09 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.